Conspectus Lipid nanoparticles (LNPs) are a type of lipid vesicles that possess a
homogeneous lipid core. These vesicles are widely used in small-molecule drug and …

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …

RNA-based therapeutics have shown great promise in treating a broad spectrum of
diseases through various mechanisms including knockdown of pathological genes …

In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus
disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome …

Harnessing mRNA–lipid nanoparticles (LNPs) to treat patients with cancer has been an
ongoing research area that started before these versatile nanoparticles were successfully …

mRNA Lipid nanoparticles (LNPs) have recently been propelled onto the center stage of
therapeutic platforms due to the success of the SARS-CoV-2 mRNA LNP vaccines (mRNA …

Decentralized manufacture of thermostable mRNA vaccines in a microneedle patch (MNP)
format could enhance vaccine access in low-resource communities by eliminating the need …

During the COVID-19 pandemic, Pfizer-BioNTech and Moderna successfully developed
nucleoside-modified mRNA lipid nanoparticle (LNP) vaccines. SARS-CoV-2 spike protein …

A major challenge to advance lipid nanoparticles (LNPs) for RNA therapeutics is the
development of formulations that can be produced reliably across the various scales of drug …

Lipid nanoparticle (LNP)-formulated nucleoside-modified mRNA vaccines have proven to be
very successful in the fight against the coronavirus disease 2019 (COVID-19) pandemic …